Journal article

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors

Amelia K Smit, Ainsley J Newson, Rachael L Morton, Michael Kimlin, Louise Keogh, Matthew H Law, Judy Kirk, Suzanne Dobbinson, Peter A Kanetsky, Georgina Fenton, Martin Allen, Phyllis Butow, Kate Dunlop, Lyndal Trevena, Serigne Lo, Jacqueline Savard, Hugh Dawkins, Sarah Wordsworth, Mark Jenkins, Graham J Mann Show all

Contemporary Clinical Trials | ELSEVIER SCIENCE INC | Published : 2018


BACKGROUND: Reducing ultraviolet radiation (UV) exposure and improving early detection may reduce melanoma incidence, mortality and health system costs. This study aims to evaluate the efficacy and cost-effectiveness of providing information on personal genomic risk of melanoma in reducing UV exposure at 12 months, according to low and high traditional risk. METHODS: In this randomized controlled trial, participants (target sample = 892) will be recruited from the general population, and randomized (1:1 ratio, intervention versus control). Intervention arm participants provide a saliva sample, receive personalized melanoma genomic risk information, a genetic counselor phone call, and an educ..

View full abstract


Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by NHMRC

Awarded by Cancer Institute NSW

Awarded by NHMRC Sidney Sax Fellowship

Funding Acknowledgements

This study is funded by the National Health and Medical Research Council of Australia (NHMRC; project grant 1129822). AEC received Career Development Fellowships from the NHMRC (1147843) and Cancer Institute NSW (15/CDF/1-14). AKS received a Research Training Program (RTP) Stipend Scholarship and a Merit Top Up Scholarship from the University of Sydney, and a Top Up Scholar Award from the Sydney Catalyst Translational Cancer Research Centre. RLM received funding from an NHMRC Sidney Sax Fellowship (1054216). MGK is supported through a Cancer Council Queensland Professorial Chair. We thank Professor Bruce Armstrong for initial feedback on the study design. The study has been endorsed by the Australian and New Zealand Melanoma Trials Group, ANZMTG 03.17.